1. Home
  2. SNGX

as 10-14-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Founded: 1987 Country:
United States
United States
Employees: N/A City: PRINCETON
Market Cap: 10.1M IPO Year: 1987
Target Price: $6.00 AVG Volume (30 days): 2.9M
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.75 EPS Growth: N/A
52 Week Low/High: $1.09 - $6.23 Next Earning Date: 11-07-2025
Revenue: N/A Revenue Growth: -85.78%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

SNGX Daily Stock ML Predictions

Stock Insider Trading Activity of Soligenix Inc. (SNGX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
SCHABER CHRISTOPHER J SNGX CHAIRMAN, CEO AND PRESIDENT Oct 2 '25 Buy $1.32 15,132 $19,999.96 15,511

Share on Social Networks: